Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit
- PMID: 17949339
- DOI: 10.1111/j.1399-302X.2007.00373.x
Induction of immune responses and prevention of alveolar bone loss by intranasal administration of mice with Porphyromonas gingivalis fimbriae and recombinant cholera toxin B subunit
Abstract
Introduction: Adult periodontitis is initiated by specific periodontal pathogens represented by Porphyromonas gingivalis; however, an effective measure for preventing the disease has not yet been established. In this study, the effectiveness of a vaccine composed of fimbriae of P. gingivalis and recombinant cholera toxin B subunit (rCTB) was evaluated using BALB/c mice.
Methods: Fimbriae and rCTB were co-administered intranasally to BALB/c mice on days 0, 14, 21, and 28. On day 35, mice were sacrificed to determine immunoglobulin levels in serum, saliva, and nasal and lung extracts by enzyme-linked immunosorbent assay. The prevention effect of the vaccine on P. gingivalis-induced periodontitis in mice was evaluated by measuring alveolar bone loss.
Results: The rCTB significantly increased serum immunoglobulin (Ig)A levels when mice were administered with a minimal amount (0.5 microg) of the fimbrial antigen. The adjuvant effect on serum IgG production was indistinct because the minimal amount of the antigen still induced a large amount of IgG. In contrast to systemic responses, a fimbria-specific secretory IgA response was strongly induced by co-administration of rCTB and 0.5 microg fimbriae; the same amount of the antigen alone scarcely induced a response. Histopathological examination revealed IgA-positive plasma cells in the nasal mucosal tissue but no observable mast cells in the area. In addition, nasal administration of the fimbrial vaccine significantly protected the mice from P. gingivalis-mediated alveolar bone loss.
Conclusion: Nasal vaccination with a combination of fimbriae and rCTB can be an effective means of preventing P. gingivalis-mediated periodontitis.
Similar articles
-
[Studies on the induction of the humoral immune responses to Bacteroides gingivalis fimbrial antigen in mice].Osaka Daigaku Shigaku Zasshi. 1990 Jun;35(1):60-77. Osaka Daigaku Shigaku Zasshi. 1990. PMID: 1983739 Japanese.
-
Transcutaneous immunization with a 40-kDa outer membrane protein of Porphyromonas gingivalis induces specific antibodies which inhibit coaggregation by P. gingivalis.Vaccine. 2005 Mar 31;23(19):2513-21. doi: 10.1016/j.vaccine.2004.10.036. Vaccine. 2005. PMID: 15752838
-
Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.Virology. 2008 Oct 25;380(2):412-20. doi: 10.1016/j.virol.2008.08.002. Epub 2008 Sep 10. Virology. 2008. PMID: 18786689
-
Immune responses and vaccination against periodontal infections.J Clin Periodontol. 2005;32 Suppl 6:39-53. doi: 10.1111/j.1600-051X.2005.00800.x. J Clin Periodontol. 2005. PMID: 16128828 Review.
-
Intranasal immunization with Porphyromonas gingivalis and atherosclerosis.Immunopharmacol Immunotoxicol. 2009;31(3):352-7. doi: 10.1080/08923970902798140. Immunopharmacol Immunotoxicol. 2009. PMID: 19555215 Review.
Cited by
-
Production of Monoclonal Antibodies Specific to FimA of Porphyromonas gingivalis and Their Inhibitory Activity on Bacterial Binding.Immune Netw. 2009 Oct;9(5):203-7. doi: 10.4110/in.2009.9.5.203. Epub 2009 Oct 30. Immune Netw. 2009. PMID: 20157608 Free PMC article.
-
Porphyromonas gingivalis Vaccine: Antigens and Mucosal Adjuvants.Vaccines (Basel). 2024 Jun 4;12(6):619. doi: 10.3390/vaccines12060619. Vaccines (Basel). 2024. PMID: 38932348 Free PMC article. Review.
-
Immunization with cell-free-generated vaccine protects from Porphyromonas gingivalis-induced alveolar bone loss.J Clin Periodontol. 2019 Feb;46(2):197-205. doi: 10.1111/jcpe.13047. Epub 2019 Jan 31. J Clin Periodontol. 2019. PMID: 30578564 Free PMC article.
-
Future Drug Targets in Periodontal Personalised Medicine-A Narrative Review.J Pers Med. 2022 Feb 28;12(3):371. doi: 10.3390/jpm12030371. J Pers Med. 2022. PMID: 35330371 Free PMC article. Review.
-
A Porphyromonas gingivalis Capsule-Conjugate Vaccine Protects From Experimental Oral Bone Loss.Front Oral Health. 2021 Jul 5;2:686402. doi: 10.3389/froh.2021.686402. eCollection 2021. Front Oral Health. 2021. PMID: 35048031 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous